From Wikipedia, the free encyclopedia
Chemical compound; modulator of the cannabinoid CB1 receptor
Pharmaceutical compound
GAT100 |
|
3-ethyl-5-isothiocyanato-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-carboxamide
|
| CAS Number | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
|
| Formula | C25H28N4OS |
|---|
| Molar mass | 432.59 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
CCc1c([nH]c2ccc(cc12)N=C=S)C(=O)NCCc3ccc(cc3)N4CCCCC4
|
InChI=1S/C25H28N4OS/c1-2-21-22-16-19(27-17-31)8-11-23(22)28-24(21)25(30)26-13-12-18-6-9-20(10-7-18)29-14-4-3-5-15-29/h6-11,16,28H,2-5,12-15H2,1H3,(H,26,30) Key:YIYLMDVRSNXYOT-UHFFFAOYSA-N
|
GAT100 is a negative allosteric modulator of the cannabinoid CB1 receptor.[1][2]
- ^ Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, et al. (January 2016). "Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)". Journal of Medicinal Chemistry. 59 (1): 44–60. doi:10.1021/acs.jmedchem.5b01303. PMC 4716578. PMID 26529344.
- ^ Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, et al. (June 2016). "Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe". ACS Chemical Neuroscience. 7 (6): 776–98. doi:10.1021/acschemneuro.6b00041. PMC 5358098. PMID 27046127.
|
|---|
Phytocannabinoids
(comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols | |
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-8-tetrahydrocannabinols | |
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic
cannabinoid
receptor
agonists /
neocannabinoids | Classical cannabinoids
(dibenzopyrans) | |
|---|
Non-classical
cannabinoids | |
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles | |
|---|
| Benzoylindoles | |
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids | |
|---|
Indazole-3-
carboxamides | |
|---|
| Indole-3-carboxamides | |
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles | |
|---|
| Naphthoylpyrroles | |
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles | |
|---|
| Phenylacetylindoles | |
|---|
| Pyrazolecarboxamides | |
|---|
Tetramethylcyclo-
propanoylindazoles | |
|---|
Tetramethylcyclo-
propanoylindoles | |
|---|
| Others | |
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands | |
|---|
Endocannabinoid
enhancers
(inactivation inhibitors) | |
|---|
Anticannabinoids
(antagonists/inverse
agonists/antibodies) | |
|---|
|
|
|---|
Receptor
(ligands) | | CB1Tooltip Cannabinoid receptor type 1 | Agonists
(abridged,
full list) | |
|---|
| Inverse agonists | |
|---|
| Antagonists | |
|---|
|
|---|
| CB2Tooltip Cannabinoid receptor type 2 | | Agonists |
- 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin · β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP 55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Lenabasum (anabasum)
- Magnolol
- MDA-19
- Nabitan
- NADA
- Olorinab (APD-371)
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
|---|
| Antagonists | |
|---|
|
|---|
NAGly
(GPR18) | |
|---|
| GPR55 | |
|---|
| GPR119 | |
|---|
|
|---|
Transporter
(modulators) | | eCBTsTooltip Endocannabinoid transporter | |
|---|
|
|---|
Enzyme
(modulators) | |
|---|
| Others |
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
|---|
|
